Skip to content

The Role of Tumor-associated Macrophages in Colorectal Liver Metastases

Search for the Clinical Significance of Tumor-associated Macrophages in Patients With Colorectal Liver Metastases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03888638
Enrollment
101
Registered
2019-03-25
Start date
2015-01-01
Completion date
2019-03-01
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Colorectal Liver Metastases, Immunotherapy, Liver Metastases

Brief summary

Colorectal cancer is a major cause of mortality worldwide. Most patients develop colorectal liver metastases (CLM), and for such patients hepatectomy combined with chemotherapy may be curative. Nevertheless, in the era of precision medicine there is a critical need of prognostic markers to cope with the heterogeneity of CLM patients. Tumor-associated macrophages (TAMs) pave the way to tissue invasion and intravasation providing a nurturing microenvironment formetastases. The quantification of immune landscape of tumors has provided novel prognostic indicators of cancer progression, and the quantification of TAMs might explain the heterogeneity of CLM patients. Here, we will investigate the development of a new diagnostic tool based on TAMs with the aim to define the causative role of TAMs in CLM patients. This will open new clinical scenarios both for the diagnosis, therapy and prognosis, leading to the refinement of the therapeutic output in a personalized medicine perspective.

Detailed description

Some preliminary data produced by the research team from Humanitas Clinical and Research Center in Milan (ITALY) have shown that TAMs in CLM are heterogeneous and that their diversity can be distinguished based on their morphology and functionality. Therefore, TAMs may represent an additional tool in the definition of the biology and prognosis of CLM patients. This preliminary finding provides us with the rationale to undertake a prospective study on a large series of CLM patients surgically resected by our unit aimed at validating the promisingcorrelation between different TAMs phenotypes and patients prognosis. The characterization of the diversity of TAMs in CLM will be refined using state of the art technology, including multi-parametric flow cytometry, single cell RNA sequencing (scRNA-seq) transcriptional profiling, metabolomic, and proteomic analyses. The expected findings will allow us to develop a new diagnostic tool based on TAMs features, which will open the way to new criteria for patient stratification and for the design of new targeted therapies in a personalized medicine perspective.

Interventions

PROCEDUREHepatectomy

Removal of a part of the liver because of tumor

Sponsors

Humanitas Clinical and Research Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with colorectal liver metastases undergoing hepatectomy * Full clinical, surgical, pathological and follow-up data * Availability of tissues for the analysis

Exclusion criteria

* Missing (any) data * Combination of radiofrequency or microwave ablation plus surgery

Design outcomes

Primary

MeasureTime frameDescription
SurvivalFrom date of surgery until the date of first documented progression or date of death from any cause, which ever came first assessed up to 72 months]Analysis of survival after hepatic resection for colorectal liver metastases according with the tumor-associated macrophages characteristics

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026